Aprea Therapeutics, Inc.
APRE
$0.80
-$0.04-4.32%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.39% | -90.41% | -80.99% | -62.76% | -34.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.39% | -90.41% | -80.99% | -62.76% | -34.08% |
| Cost of Revenue | -30.00% | -39.77% | -24.78% | -7.26% | 15.31% |
| Gross Profit | 23.33% | 32.51% | 14.04% | -2.14% | -24.24% |
| SG&A Expenses | 7.79% | 3.77% | 0.28% | -15.90% | -15.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.41% | -23.20% | -14.55% | -11.03% | 1.08% |
| Operating Income | 10.63% | 17.55% | 7.58% | 6.44% | -4.24% |
| Income Before Tax | 11.14% | 15.10% | 2.77% | 3.47% | -7.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.14% | 15.10% | 2.77% | 3.47% | -7.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.14% | 15.10% | 2.77% | 3.47% | -7.13% |
| EBIT | 10.63% | 17.55% | 7.58% | 6.44% | -4.24% |
| EBITDA | 10.65% | 17.57% | 7.59% | 6.45% | -4.22% |
| EPS Basic | 53.42% | 34.76% | 16.94% | 23.87% | 23.79% |
| Normalized Basic EPS | 53.42% | 34.76% | 16.93% | 23.86% | 23.79% |
| EPS Diluted | 53.42% | 34.76% | 16.94% | 23.87% | 23.79% |
| Normalized Diluted EPS | 53.42% | 34.76% | 16.93% | 23.86% | 23.79% |
| Average Basic Shares Outstanding | 243.03% | 46.19% | 18.65% | 23.18% | 36.14% |
| Average Diluted Shares Outstanding | 243.03% | 46.19% | 18.65% | 23.18% | 36.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |